<SEC-DOCUMENT>0001193125-22-023401.txt : 20220131
<SEC-HEADER>0001193125-22-023401.hdr.sgml : 20220131
<ACCEPTANCE-DATETIME>20220131162938
ACCESSION NUMBER:		0001193125-22-023401
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220131
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
FILED AS OF DATE:		20220131
DATE AS OF CHANGE:		20220131

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		22574369

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d275986d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amgn="http://www.amgen.com/20220131" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2022-01-31_to_2022-01-31">AMGEN INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-01-31_to_2022-01-31">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-01-31_to_2022-01-31">0000318154</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="amgn-20220131.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-01-31_to_2022-01-31"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-31</xbrli:startDate> <xbrli:endDate>2022-01-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2022-01-31_to_2022-01-31_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-31</xbrli:startDate> <xbrli:endDate>2022-01-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2022-01-31_to_2022-01-31_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-31</xbrli:startDate> <xbrli:endDate>2022-01-31</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-01-31_to_2022-01-31">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-01-31_to_2022-01-31" format="ixt:datemonthdayyearen">January 31, 2022</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">Amgen Inc.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-01-31_to_2022-01-31" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-01-31_to_2022-01-31">001-37702</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-01-31_to_2022-01-31">95-3540776</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-01-31_to_2022-01-31">One Amgen Center Drive</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-01-31_to_2022-01-31">Thousand Oaks</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-01-31_to_2022-01-31" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-01-31_to_2022-01-31">91320-1799</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-01-31_to_2022-01-31">(805)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-01-31_to_2022-01-31">447-1000</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-01-31_to_2022-01-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-01-31_to_2022-01-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-01-31_to_2022-01-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-01-31_to_2022-01-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-01-31_to_2022-01-31_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common stock, $0.0001 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-01-31_to_2022-01-31_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">AMGN</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-01-31_to_2022-01-31_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-01-31_to_2022-01-31_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">2.000% Senior Notes due 2026</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-01-31_to_2022-01-31_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">AMGN26</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-01-31_to_2022-01-31_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2). Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-01-31_to_2022-01-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with the settlement of the previously disclosed litigation between Amgen Inc. (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;) and Novartis AG (&#8220;<span style="text-decoration:underline">Novartis</span>,&#8221; and together with the Company, the &#8220;<span style="text-decoration:underline">Parties</span>&#8221;)<sup style="font-size:85%; vertical-align:top">1</sup>, the Parties have modified the terms of the Parties&#8217; previously reported collaboration agreements<sup style="font-size:85%; vertical-align:top">2</sup> in the manner described below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;1.01 Entry into a Material Definitive Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;31, 2022, the Company entered into Amendment No.&#160;3 (the &#8220;<span style="text-decoration:underline">Amendment</span>&#8221;) to the Exclusive License and Collaboration Agreement, dated August&#160;28, 2015, as amended on April&#160;21, 2017, by and between the Parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Amendment (and as a result of the termination of the Amended and Restated Collaboration Agreement, dated June&#160;2, 2021 (the &#8220;<span style="text-decoration:underline">U.S. Collaboration Agreement</span>&#8221;), by and between the Parties, described under Item 1.02 hereof), Novartis will hold sole rights to commercialize Aimovig outside of the United States and Japan, Amgen will no longer pay royalties to Novartis on sales of Aimovig in the United States, and the Parties will no longer share the costs of commercialization of Aimovig in the United States. The Parties will continue to share development expenses worldwide. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Amendment and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Amendment, which is filed as Exhibit 10.1 hereof and which is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;1.02 Termination of a Material Definitive Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;31, 2022, concurrent with the entry into the Amendment described under Item 1.01 hereof, the Company terminated the U.S. Collaboration Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:90%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:94%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d275986dex101.htm">Amendment No.&#160;3 to the Exclusive License and Collaboration Agreement, dated April&#160;21, 2017, by and between Amgen Inc. and Novartis Pharma AG (portions of the exhibit have been omitted because they are both (i)&#160;not material and (ii)&#160;is the type of information that the Company treats as private or confidential.) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:85%; vertical-align:top">1</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">See Amgen&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2020, Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements; and Notes 13 and 14, Contingencies and commitments, to the condensed consolidated financial statements in Amgen&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the periods ended June&#160;30, 2021 and September&#160;30, 2021, respectively. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:85%; vertical-align:top">2</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">See Amgen&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed on April&#160;24, 2017; and Exhibits 10.41 through 10.43, and 10.39 in Amgen&#8217;s Quarterly Reports on Form <span style="white-space:nowrap">10-Q</span> for the quarters ended June&#160;30, 2017 and June&#160;30, 2021, respectively. </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap">AMGEN INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Date: January&#160;31, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan P. Graham</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Jonathan P. Graham</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Executive Vice President, General Counsel and Secretary</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d275986dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I)&nbsp;NOT MATERIAL AND
(II)&nbsp;IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AMENDMENT No.&nbsp;3 </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>to the Exclusive License and Collaboration Agreement </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>between Novartis Pharma AG and Amgen Inc. </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Amendment No.&nbsp;3 (&#147;<B>Amendment</B>&#148;) is entered into as of January&nbsp;31, 2022, with effect from and after January&nbsp;1, 2022<B>
</B>(&#147;<B>Amendment No.</B><B></B><B>&nbsp;3 Effective Date</B>&#148;) by and between Novartis Pharma AG a Swiss corporation having its principal place of business at Lichtstrasse 35, <FONT STYLE="white-space:nowrap">CH-4056</FONT> Basel,
Switzerland<B><I> </I></B>(&#147;<B>Novartis</B>&#148;) and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA (&#147;<B>Amgen</B>&#148;). Novartis and Amgen
are each referred to individually as a &#147;<B>Party</B>&#148; and together as the &#147;<B>Parties</B>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, Novartis and
Amgen are parties to an Exclusive License and Collaboration Agreement dated August&nbsp;28, 2015 and amended as of April&nbsp;21, 2017 (the &#147;<B>Agreement</B>&#148;) concerning the development and commercialization of the Licensed Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, Amgen and Novartis are parties to that certain Collaboration Agreement, dated April&nbsp;21, 2017, as amended and restated as of
June&nbsp;2, 2021, with respect to the Commercialization of, and Medical Affairs Activities for, Franchise Product 1 in the United States (the &#147;<B>US Collaboration Agreement</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, simultaneously herewith, the Parties are entering into a Confidential Settlement Agreement and Release and a Stipulation of Dismissal
to resolve the litigation captioned <I>Novartis Pharma AG v. Amgen, Inc.</I>, No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:19-CV-2993</FONT></FONT> (S.D.N.Y.) and <I>Amgen, Inc. v. Novartis Pharma AG</I>, No. <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:19-CV-3003</FONT></FONT> (the &#147;<B>Settlement</B>&#148;) and (ii)&nbsp;mutually agreeing to terminate the US Collaboration Agreement pursuant to the entry into an agreement to
terminate the US Collaboration Agreement (the &#147;<B>US Termination Agreement</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties mutually desire to
amend, modify and restate certain terms and conditions of the Agreement in connection with the Settlement and the US Termination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, in consideration of the premises and the mutual covenants herein contained, it is mutually agreed as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise defined herein, capitalized words in this Amendment shall have the meaning attributed to them in the Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AMENDMENTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Parties agree that, as of the Amendment No.&nbsp;3 Effective Date, the Agreement is amended as set forth in this Section&nbsp;2. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Solely with respect to those provisions of the Agreement not hereby amended in this Amendment, Novartis&#146;
and Amgen&#146;s rights and obligations under the Agreement with respect to Franchise Product 1 in the United States are subject to the terms and conditions set forth in the US Termination Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following sentence shall be added to the Recitals: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;WHEREAS, Amgen and Novartis have mutually agreed to terminate the US Collaboration Agreement as of the Amendment No.&nbsp;3 Effective
Date.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following definitions shall be added to Article 1 in appropriate alphabetical order: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Costs</I>&#148; means both internal and external costs and expenses (including the cost of allocated FTEs at the applicable U.S. FTE
Rate). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>FP1</I> <I>Development Costs</I>&#148; has the meaning set forth in Section&nbsp;9.7.2(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>FP1</I> <I>Development Cost Cap</I>&#148; has the meaning set forth in Section&nbsp;9.7.2(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>MSL Cap</I>&#148; has the meaning set forth in Section&nbsp;9.7.2(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>United States Brand Plan</I>&#148; means the high-level cross-functional Commercialization plan developed by Amgen (subject to review
of the JSC) for Franchise Product 1 in the United States and consistent with the Global Brand Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>U.S. FTE Rate</I>&#148; means
[***] per FTE per year (as of the Amendment No.&nbsp;3<B> </B>Effective Date), increasing by [***] of the then-current U.S. FTE Rate on [***] and each subsequent Calendar Year. The U.S. FTE Rate includes costs associated with salaries, payroll
taxes, bonuses, benefits, recruiting, relocation, employee stock option programs or stock grants, retirement programs, and applicable overhead (e.g., facilities, operating supplies, travel and training). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>U.S. Medical Affairs Activities Costs</I>&#148; means Costs incurred by Amgen and its Affiliates during the Term associated with
Medical Affairs Activities in the United States to the extent incurred in accordance with the applicable Development Budget. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>U.S.
Medical Affairs</I> <I>Completion Date</I>&#148; has the meaning set forth in Section&nbsp;9.7.2(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>U.S. Medical Affairs <FONT
STYLE="white-space:nowrap">Non-MSL</FONT> Costs</I>&#148; means the U.S. Medical Affairs Activity Costs that are not related to the FTE costs of the Medical Liaisons for Franchise Product 1 in the United States, which includes by way of example the
activities set forth in subclauses (ii)&nbsp;and (iii) of Section&nbsp;1.103 (Medical Affairs Activities). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;1.33 of the Agreement is hereby deleted in its entirety and replaced with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;1.33 <I>&#147;</I><I>Development Costs</I><I>&#148;</I><I> </I>means the direct costs incurred by a Party and its
Affiliates during the Term and pursuant to this Agreement for the Development of and Medical Affairs Activities with respect to a Licensed Product(s), calculated as the sum of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(i)&nbsp;Out-of-Pocket</FONT></FONT> Development Expenses, (ii)&nbsp;Development FTE Costs and (iii)&nbsp;Other Development Expenses, each only to the extent incurred in accordance
with the Development Plan and Development Budget after the Effective Date.&nbsp;For clarity, &#147;Development Costs&#148; does not include any costs associated with conducting any Phase 4 Clinical Trials or lifecycle management activities unless
the Parties otherwise agree to include a Phase 4 Clinical Trial or lifecycle management activities in the Development Plan.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;3.2.5 of the Agreement is hereby deleted in its entirety and replaced with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;3.2.5 <I>JSC Oversight of the United States</I>. The JSC shall review and discuss the United States Brand Plan,
solely to ensure alignment with the Global Brand Plan. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The final sentence of Section&nbsp;3.2.6 of the Agreement is hereby deleted in its entirety and replaced with
the following: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;In connection with the transition of the Commercialization and Medical Affairs Activities with
respect to Franchise Product 1 in the Field in the United States solely to Amgen, each of the Joint US Leadership Team, US Collaboration Team, US Medical Affairs JPT, US Committee and Joint Compliance Contacts (each, as defined in the US
Collaboration Agreement) have been disbanded as of June&nbsp;2, 2021.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;3.5.3.1 of the Agreement is hereby deleted in its entirety and replaced with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;3.5.3.1 The Amgen <FONT STYLE="white-space:nowrap">Co-Chair</FONT> shall have the deciding vote with respect to
the Global Brand Plans and all Commercialization matters with respect to the Licensed Products outside the Territory.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The final sentence of Section&nbsp;3.7 of the Agreement is hereby deleted in its entirety.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;3.8 of the Agreement is hereby deleted in its entirety and replaced with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;3.8 <U>Outside the Territory</U>. Unless expressly set forth in this Agreement otherwise, Amgen shall have sole
decision-making authority with regard to Development, regulatory, Medical Affairs Activities, Manufacturing and Commercialization of Licensed Products outside the Territory. Novartis and its Affiliates shall not Commercialize or conduct Medical
Affairs Activities with respect to Licensed Products in any country outside the Territory.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The last sentence of Section&nbsp;4.6 of the Agreement is hereby deleted in its entirety and replaced with the
following: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Amgen agrees that it shall not seek to register or obtain ownership rights in any Novartis Housemark or
Licensed Novartis Trademark (or confusingly similar trademark) and Novartis agrees that it shall not seek to register or obtain ownership rights in any Amgen Housemark or Licensed Amgen Trademark or any trademark used by Amgen in connection with the
applicable Licensed Product outside the Territory in any indication (or confusingly similar trademark to any of the foregoing).&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;4.8 of the Agreement is hereby deleted in its entirety and replaced with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;4.8 <U>Retained Rights and Limitations</U>. No rights to either Party&#146;s patents, trademarks or other
proprietary rights are granted pursuant to this Agreement except as expressly set forth herein, and all other rights are reserved. Subject to Section&nbsp;2.3 (Development Prior to Option Exercise Date), Novartis shall not research, Develop,
Manufacture, conduct Medical Affairs Activities with respect to or Commercialize Franchise Product 3 prior to the Option Exercise Date or any Licensed Product outside the Territory and Amgen shall not research, Develop, conduct Medical Affairs
Activities with respect to or Commercialize any Licensed Product inside the Territory, in each case, other than as expressly set forth in this Agreement (including under a Development Plan). Notwithstanding the licenses granted in this Article 4
(Grant of License), each Party retains rights to perform (itself or through its Affiliates or contractors) its obligations under this Agreement.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The proviso in the third to last sentence of Section&nbsp;5.1 of the Agreement is hereby deleted in its
entirety. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;5.4.5 of the Agreement is hereby deleted in its entirety. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;6.3 of the Agreement is hereby deleted in its entirety and replaced with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;6.3 <U>Commercialization </U><U>Outside the Territory</U>. Except as expressly set forth in this Agreement, and
subject to the US Termination Agreement, Amgen shall be solely responsible for the Commercialization of the Licensed Products outside the Territory and the costs thereof and Novartis shall have no rights or obligations with respect thereto.&#148;
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;7.4 of the Agreement is hereby deleted in its entirety and replaced with the following:
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;7.4 <U>[***] Divestiture</U>. The notice provided pursuant to Section&nbsp;7.3
(Post-Effective Date Affiliates) shall include a notification as to whether such Party intends to: (i)&nbsp;Divest the Distracting Program, in which case such Party shall hold separate such Distracting Program (including Segregating such Distracting
Program from the Collaboration) and use its commercially reasonable, good-faith efforts to Divest such Distracting Program; (ii) [***] such Distracting Program, in which case such Party shall [***] all activities of such program within [***] after
the closing of the Distracting Transaction, during which period such Party shall hold separate such Distracting Program (including Segregating such Distracting Program from the Collaboration); or (iii)&nbsp;in the case of Amgen only, [***] or, in
the case of Novartis, [***], in each case within [***] after the closing of the Distracting Transaction. In the event such Party selects to Divest the Distracting Program under subsection (i)&nbsp;and fails to complete such Divestiture within [***]
of the closing of the Distracting Transaction, then such Party shall be deemed to have chosen to terminate such Distracting Program and shall promptly, and no later than within [***] days, comply with the requirements of subsection
(ii)&nbsp;above.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The first sentence of Section&nbsp;9.7.1 of the Agreement is hereby deleted in its entirety and replaced with
the following: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;In addition to the other payments referenced herein with respect to each Licensed Product, and
subject to Section&nbsp;9.7.2 (Franchise Product 1 Development Cost Cap) with respect to Franchise Product 1, Novartis shall bear the percentage of Amgen Development Costs set forth in the &#147;Novartis Share&#148; column of the applicable chart
below and Amgen shall bear the percentage of Novartis Development Costs set forth in the &#147;Amgen Share&#148; column of the chart below, in each case, that are included in the applicable Development Budget.&#148; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following language shall be added as a new Section&nbsp;9.7.2 of the Agreement (and the remainder of
Section&nbsp;9.7 to be renumbered accordingly): </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Franchise Product 1 Development Cost Cap</I>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the provisions of this Section&nbsp;9.7.2: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i) Novartis shall pay [***] of the Franchise 1 Product Development Costs (including U.S. Medical Affairs Activities Costs) (&#147;<I>FP1
Development Costs</I>&#148;) until such time as the FP1 Development Costs otherwise allocated to Amgen under the &#147;Amgen Share&#148; column of the chart in Section&nbsp;9.7.1 (Development Cost Sharing) equals [***] in the aggregate (the
&#147;<I>FP1</I> <I>Development Cost Cap</I>&#148;); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii) After the FP1 Development Cost Cap has been reached, each Party shall pay
[***] of the FP1 Development Costs otherwise allocated to Amgen under the &#147;Amgen Share&#148; column of the chart in Section&nbsp;9.7.1 (Development Cost Sharing). For clarity, after the FP1 Development Cost Cap has been reached, Novartis will
effectively pay [***] of all Development Costs for Franchise Product 1 (which includes (1) [***] of all Development Costs under the &#147;Novartis Share&#148; column of the chart in Section&nbsp;9.7.1 (Development Cost Sharing) for Franchise Product
1 and (2) [***] of all Development Costs under the &#147;Amgen Share&#148; column of the chart in Section&nbsp;9.7.1 (Development Cost Sharing) for Franchise Product 1) and Amgen will effectively pay [***] of all Development Costs for Franchise
Product 1. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding the provisions of Section&nbsp;9.7.2(a): </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i) Novartis shall have no obligation to fund Development Costs (A)&nbsp;solely relating to
Development of Franchise Product 1 for Regulatory Approval in Japan to the extent such costs are not included in the Development Budget as of the Amendment No.&nbsp;2 Effective Date, or (B) [***]; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii) upon the later of (A)&nbsp;the FP1 Development Cost Cap having been achieved, and (B) [***] (such later time, the &#147;<I>U.S. Medical
Affairs</I> <I>Completion Date</I>&#148;), [***] shall no longer be considered Development Costs and all [***] shall be borne [***] by Amgen. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iii) Until the occurrence of the U.S. Medical Affairs Completion Date, (1)&nbsp;Amgen may [***]; (2) Amgen may [***] at the time of the
Amendment No.&nbsp;3 Effective Date, on a <I>pro rata</I> basis for partial Calendar Years; and (3)&nbsp;Novartis is obligated to fund the foregoing [***] attributable to clauses (1)&nbsp;and (2) as part of its Development Cost funding obligations
under this Section&nbsp;9.7.2. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;9.7.3 of the Agreement (which, for clarity, is renumbered from Section&nbsp;9.7.2 of the Agreement
pursuant to Section&nbsp;2.17 above) is hereby deleted in its entirety and replaced with the following: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Annual
Development Budget Overruns</I>. With respect to each Licensed Product, each Party shall promptly notify the other Party upon becoming aware that its Development Costs to be incurred in performing the applicable Development Plan for a Calendar Year
will be in excess of the amounts budgeted to be incurred by or on behalf of such Party for its activities in the applicable Annual Development Budget. If the aggregate Development Costs incurred by a Party for performing the applicable Development
Plan for a Calendar Year exceed the amounts budgeted to be incurred by or on behalf of such Party for its activities in the applicable Annual Development Budget, the other Party shall reimburse the performing Party for (i)&nbsp;the applicable
percentage set forth above of such excess, and (ii)&nbsp;in the case of Franchise Product 1, the applicable percentage set forth in Section&nbsp;9.7.2 of such excess (<I>i.e.</I>, Novartis reimbursing for [***] and thereafter, Novartis reimbursing
for [***] and Amgen reimbursing for [***]); <I>provided </I>that (a)&nbsp;in no event shall Novartis be responsible for reimbursement for such excesses to the extent the Amgen Development Costs in performing the Development Plan (I)&nbsp;for [***],
exceed the amounts budgeted to be incurred by or on behalf of Amgen for its activities in the applicable Annual Development Budget for [***], and (II)&nbsp;for [***], exceed the amounts budgeted to be incurred by or on behalf of Amgen for its
activities in the applicable Annual Development Budget for such Calendar Year by more than [***] percent ([***]%) and (b)&nbsp;in no event shall Amgen be responsible for reimbursement for such excesses to the extent the Novartis Development Costs in
performing the Development Plan for a Calendar Year exceed the amounts budgeted to be incurred by or on behalf of Novartis for its activities in the applicable Annual Development Budget for such Calendar Year by more than [***] percent ([***]%);
<I>provided </I>that a Party shall be responsible for reimbursement for such excesses to the extent that the Amgen Development Costs or Novartis Development Costs, as the case may be, are attributable to (I)&nbsp;a change in applicable Law,
(II)&nbsp;a Force Majeure event, (III)&nbsp;[***], (IV)&nbsp;[***], or (V)&nbsp;a mutually agreed amendment to the applicable Development Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;9.7.4 of the Agreement is hereby deleted in its entirety and replaced with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;9.7.4 <I>Payments</I>. Based on the report received from the other Party pursuant to Section&nbsp;9.7.3 (Reports),
the Party which has borne more than its share of Development Costs as determined pursuant to Section&nbsp;9.7.1 (General) and, solely with respect to Development Costs with respect to Franchise Product 1, Section&nbsp;9.7.2 (Franchise Product 1
Development Cost Cap) shall issue an invoice to the owing Party for such excess amount in accordance with Section&nbsp;9.10 (Payment Method) within [***] after receiving the other Party&#146;s report pursuant to Section&nbsp;9.7.3 (Reports).&#148;
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The first two sentences of Section&nbsp;9.11 (Audits) of the Agreement is hereby deleted in its entirety and
replaced with the following: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Novartis shall keep complete and accurate records pertaining to Novartis Development
Costs and to the underlying revenue and expenses data relating to the calculation of Net Sales for the Licensed Products in the Territory in sufficient detail to permit Amgen to reasonably confirm the accuracy of all payments due hereunder,
including Amgen&#146;s obligation to reimburse Novartis for Amgen&#146;s share of Novartis Development Costs pursuant to Section&nbsp;9.7 (Development Cost Sharing), including, solely with respect to Development Costs with respect to Franchise
Product 1, Section&nbsp;9.7.2 (Franchise Product 1 Development Cost Cap). Amgen shall keep complete and accurate records pertaining to Amgen Development Costs of Licensed Products in sufficient detail to permit Novartis to reasonably confirm the
accuracy of all payments due hereunder with respect to Novartis&#146;s obligation to reimburse Amgen for Novartis&#146;s share of Amgen Development Costs pursuant to Section&nbsp;9.7 (Development Cost Sharing), including, solely with respect to
Development Costs with respect to Franchise Product 1, Section&nbsp;9.7.2 (Franchise Product 1 Development Cost Cap).&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;10.2.2 of the Agreement is hereby deleted in its entirety and replaced with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;10.2.2 <I>Outside</I><I> Territory</I>.<I> </I>Amgen shall control and be solely responsible for all Patent and
Trademark Matters with respect to its patent rights, trademark rights and other intellectual property outside the Territory, at its sole cost and expense. Amgen shall control and be solely responsible for Patent and Trademark Matters with respect to
Joint Patents outside the Territory, at its sole cost and expense. Notwithstanding the other provisions of this Section&nbsp;10.2.2 (Outside Territory), without the prior written consent of Novartis, Amgen shall not take any action (or fail to take
any action) with respect to such intellectual property or Joint Patents [***] that would reasonably be expected to [***] the Licensed Amgen Patents or the research, Development, conduct of Medical Affairs Activities with respect to, use or
Commercialization of Licensed Products [***].&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The first sentence of Section&nbsp;10.3.2 of the Agreement is hereby deleted in its entirety and replaced with
the following: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;From and after the Effective Date, with respect to Licensed Amgen Patents, Licensed Amgen
Trademarks and Joint Patents, in each case outside the Territory, (collectively, the <I>&#147;</I><I><FONT STYLE="white-space:nowrap">Ex-Territory</FONT> Patents and Trademarks</I><I>&#148;</I>) specific to Franchise Product 1 and Franchise Product
2, and from and after the Option Exercise Date, with respect to <FONT STYLE="white-space:nowrap">Ex-Territory</FONT> Patents and Trademarks specific to Franchise Product 3, if a Third Party asserts that a patent right or other right owned by it is
infringed by the manufacture, use, offer for sale, sale, or importation of the Licensed Product outside the Territory, by Amgen, Amgen shall have the sole right to defend against any such assertions at its sole cost.&#148; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;10.4.2 of the Agreement is hereby deleted in its entirety and replaced with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;10.4.2 <I>Outside</I><I> Territory</I>. Amgen shall have the sole right, but not the obligation, to enforce its
patent rights, trademark rights and other intellectual properties, and the Joint Patents outside the Territory against any actual, alleged or threatened infringement or misappropriation by Third Parties outside the Territory, and to settle any such
matters in its sole discretion subject to Section&nbsp;10.3 (Defense and Settlement of Third Party Claims). Novartis shall have no right to enforce such rights outside the Territory.&#148; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The last sentence of Section&nbsp;10.6 of the Agreement is hereby deleted in its entirety and replaced with the
following: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Amgen shall have the sole right to retain (i)&nbsp;any and all Recoveries from actions brought by Amgen
with respect to Territory Patents and Trademarks related to Franchise Product 3 prior to the Option Exercise Date, (ii)&nbsp;any and all recoveries with respect to the enforcement of any Amgen intellectual property or proprietary right or Joint
Patents outside the Territory, (iii)&nbsp;any and all Recoveries with respect to enforcement of Licensed Amgen Patents to the extent not specifically related to a Licensed Product and (iv)&nbsp;any and all Recoveries from actions brought by Amgen
after termination of this Agreement.&#148;<B><I> </I></B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.25</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The second sentence of Section&nbsp;11.1 of the Agreement is hereby deleted in its entirety and replaced with
the following: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Novartis shall have no right to and shall not utilize any Confidential Information of Amgen for
activities outside the Territory except as required under the applicable Development Plan.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.26</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;11.6.1 of the Agreement is hereby deleted in its entirety and replaced with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;present findings with respect to any Licensed Product at symposia and other meetings of healthcare professionals,
and international, national or regional congresses, conferences or meetings organized by a professional society or organization (any such occasion, a <I>&#147;Scientific Meeting&#148;</I>); <I>provided,</I> <I>however</I>, unless otherwise agreed by
the Parties, that (i)&nbsp;the Party presenting at any such Scientific Meeting shall have complied with the provisions of Section&nbsp;11.6 (Publications and Presentations) and Section&nbsp;11.7 (Scientific
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Papers, Abstracts and Posters) with respect to such presentation, and, with respect to any such Scientific Meeting at which a Party is presenting, such presenting Party shall inform the other
Party of such Scientific Meeting and where invitation is required, invite the other Party to attend such Scientific Meeting; and (ii)&nbsp;a Party shall not organize or sponsor any satellite symposia in a country (a)&nbsp;in the case of Novartis,
outside the Territory, or (b)&nbsp;in the case of Amgen, within the Territory, without the other Party&#146;s prior written consent, not to be unreasonably withheld;&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.27</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;12.3 of the Agreement is hereby deleted in its entirety and replaced with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disclaimer of Warranties</U>. EXCEPT AS SET FORTH IN THIS ARTICLE 12 (REPRESENTATIONS, WARRANTIES AND
COVENANTS), NOVARTIS AND AMGEN EXPRESSLY DISCLAIM ANY AND ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE COLLABORATION, THE LICENSED PRODUCTS, THE LICENSED AMGEN PATENTS, LICENSED AMGEN TRADEMARKS,
LICENSED AMGEN <FONT STYLE="white-space:nowrap">KNOW-HOW,</FONT> LICENSED NOVARTIS PATENTS, LICENSED NOVARTIS TRADEMARKS, LICENSED NOVARTIS <FONT STYLE="white-space:nowrap">KNOW-HOW,</FONT> THIS AGREEMENT, OR ANY OTHER SUBJECT MATTER RELATING TO
THIS AGREEMENT, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OR NONINFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS. Except as set forth in this Article 12 (Representations, Warranties and Covenants), all
licenses by Novartis to Amgen under the Licensed Novartis <FONT STYLE="white-space:nowrap">Know-How</FONT> and Licensed Novartis Patents shall be granted <FONT STYLE="white-space:nowrap">&#147;as-is&#148;</FONT> and all licenses by Amgen to Novartis
under the Licensed Amgen <FONT STYLE="white-space:nowrap">Know-How,</FONT> Licensed Amgen Trademarks and Licensed Amgen Patents shall be granted <FONT STYLE="white-space:nowrap">&#147;as-is&#148;.&#148;</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.28</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Clause (viii)&nbsp;of Section&nbsp;15.3.2 of the Agreement is hereby deleted in its entirety and replaced with
the following: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;(viii) Section&nbsp;4.2 (Licensed Novartis <FONT STYLE="white-space:nowrap">Know-How</FONT> and
Patents) (solely to the extent such intellectual property has been or is incorporated into or used in the Development, Manufacture, Medical Affairs Activities, regulatory activities or Commercialization of Licensed Products as of the date of
termination) shall survive [***];&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.29</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The last sentence of Section&nbsp;15.3.2 of the Agreement is hereby deleted in its entirety and replaced with
the following: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;In the event of any termination of this Agreement by Amgen pursuant to and as set forth in
Section&nbsp;7.4 ([***] Divestiture), (a) the licenses granted to Novartis under Section&nbsp;4.1 (Licensed Amgen Patents and <FONT STYLE="white-space:nowrap">Know-How)</FONT> and under Section&nbsp;4.5.1 (Grant to Novartis) (solely to the extent
such intellectual property has been or is incorporated into or used in the Development, Medical Affairs Activities, regulatory activities or Commercialization of Licensed Products as of the date of termination) shall survive, (b)&nbsp;Amgen shall
continue to Manufacture and supply Licensed Product for the Territory for a period of up to [***] months in accordance with the Supply Agreement, (c)&nbsp;Novartis shall continue to pay to Amgen royalties on annual Net Sales of each Licensed Product
in the Territory for each </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Calendar Year (or portion thereof) during the applicable Royalty Term pursuant to Section&nbsp;9.1 (Royalty Payments); <I>provided</I>, that the royalties set forth in Section&nbsp;9.1 (Royalty
Payments) shall [***] provided that in no event shall the royalties payable to Amgen for Franchise Product 1 [***] and for each of Franchise Product 2 and Franchise Product 3 [***], and (d)&nbsp;the Parties shall negotiate in good faith a process
for the transition of ongoing activities necessary to allow Novartis to exercise its rights under such license and allow Novartis to continue to Develop, Manufacture and Commercialize the Licensed Product in the Territory, including assistance from
Amgen for the transfer of Manufacturing to a contract manufacturing organization mutually agreed by the Parties.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.30</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;15.4 of the Agreement is hereby deleted in its entirety and replaced with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;15.4 <U>Additional Surviving Provisions</U>. In addition and without prejudice to the provisions of
Section&nbsp;15.3 (Effect of Termination) and the provisions that are expressly stated to survive termination, in the event of any expiration or termination of this Agreement the following provisions shall survive: Articles 1 (Definitions), 11
(Confidentiality and Publications) (except with respect to Section&nbsp;11.6 (Publications and Presentations), 11.7 (Scientific Papers; Abstracts and Posters), 11.8 (Deferral of Disclosures) and 11.9 (Failure to Object to Disclosure)); 13
(Limitations of Liability; Insurance); 14 (Indemnification); 15 (Term and Termination) and 16 (Miscellaneous); 9.1 (Royalty Payments) through 9.6 (No Wrongful Reductions) (inclusive) (with respect to sales made prior to such termination or, if
later, prior to completion of the transition by Novartis pursuant to Section&nbsp;15.5 (Transition Period)); 9.7 (Development Cost Sharing) (with respect to Development Costs reasonably incurred prior to such termination); 9.8 (Sublicense Payments)
(with respect to amounts incurred prior to such termination); 9.10 (Payment Method) through 9.16 (Late Payment) (inclusive); 10.1 (Ownership and Cooperation); 10.6 (Allocation of Recoveries) (with respect to periods prior to termination); and 12.3
(Disclaimer of Warranties).&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTEGRATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Except for the sections of the Agreement specifically amended hereunder, all terms and conditions of the Agreement remain and shall remain in
full force and effect. This Amendment shall hereafter be incorporated into and deemed part of the Agreement and any future reference to the Agreement shall include the terms and conditions of this Amendment. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>APPLICABLE LAW&nbsp;&amp; JURISDICTION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This Amendment shall be governed by, and construed in accordance with, the laws which govern the Agreement, and the Parties submit to the
jurisdiction and dispute resolution provisions as set forth in the Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COUNTERPARTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This Amendment may be executed in counterparts with the same effect as if both Parties had signed the same document. All such counterparts
shall be deemed an original, shall be construed together and shall constitute one and the same instrument. Signature pages of this Amendment may be exchanged by facsimile or other electronic means without affecting the validity thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Intentionally Left Blank &#150; Signature Page to Follow] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties intending to be bound have caused this Amendment to be executed by their
duly authorized representatives. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>NOVARTIS PHARMA AG</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>AMGEN INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Neil Johnston</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Murdo Gordon</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Neil Johnston</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Murdo Gordon</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Global Head BD&amp;LPharma</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Vice President, Global Commercial Operations</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January 31, 2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Date: January&nbsp;31, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gregor von Arx</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Gregor von Arx</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Global Head Legal Neuroscience</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January 31, 2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>amgn-20220131.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 2/1/2022 2:23:56 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:amgn="http://www.amgen.com/20220131"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.amgen.com/20220131"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20220131_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20220131_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20220131_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="amgn_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="amgn_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="amgn_A2.00SeniorNotesDue2026Member" name="A2.00SeniorNotesDue2026Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>amgn-20220131_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 2/1/2022 2:23:59 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="amgn-20220131.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="amgn-20220131.xsd#amgn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="amgn-20220131.xsd#amgn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="amgn-20220131.xsd#amgn_A2.00SeniorNotesDue2026Member" xlink:type="locator" xlink:label="amgn_A2.00SeniorNotesDue2026Member" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="amgn_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amgn_A2.00SeniorNotesDue2026Member" order="25" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="28.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="29.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="33.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="34.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="35.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="36.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="37.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="38.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="39.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="40.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="41.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="42.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="43.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="44.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="45.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="46.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="47.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="48.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="49.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="50.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="51.001" priority="2" use="optional" />
  </link:definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>amgn-20220131_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 2/1/2022 2:23:56 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="amgn-20220131.xsd#amgn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="amgn_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="amgn-20220131.xsd#amgn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="amgn_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:loc xlink:href="amgn-20220131.xsd#amgn_A2.00SeniorNotesDue2026Member" xlink:type="locator" xlink:label="amgn_A2.00SeniorNotesDue2026Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_A2.00SeniorNotesDue2026Member" xlink:to="amgn_A2.00SeniorNotesDue2026Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_A2.00SeniorNotesDue2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 2.00 Senior Notes Due 2026 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_A2.00SeniorNotesDue2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 2.00 Senior Notes Due 2026 [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>amgn-20220131_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 2/1/2022 2:23:56 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="amgn-20220131.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="amgn-20220131.xsd#amgn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="amgn_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="amgn-20220131.xsd#amgn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="amgn_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="amgn-20220131.xsd#amgn_A2.00SeniorNotesDue2026Member" xlink:type="locator" xlink:label="amgn_A2.00SeniorNotesDue2026Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amgn_A2.00SeniorNotesDue2026Member" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="48.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="49.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="50.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="51.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140643381786216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMGEN INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 31,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3540776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Amgen Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Thousand Oaks<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91320-1799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">447-1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member', window );">A 2.00 Senior Notes Due 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">2.000% Senior Notes due 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d275986d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amgn="http://www.amgen.com/20220131"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="amgn-20220131.xsd" xlink:type="simple"/>
    <context id="duration_2022-01-31_to_2022-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="duration_2022-01-31_to_2022-01-31_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="duration_2022-01-31_to_2022-01-31_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2022-01-31_to_2022-01-31"
      id="Hidden_dei_EntityRegistrantName">AMGEN INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2022-01-31_to_2022-01-31">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-01-31_to_2022-01-31"
      id="Hidden_dei_EntityCentralIndexKey">0000318154</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-01-31_to_2022-01-31">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-01-31_to_2022-01-31">2022-01-31</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-01-31_to_2022-01-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-01-31_to_2022-01-31">001-37702</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-01-31_to_2022-01-31">95-3540776</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-01-31_to_2022-01-31">One Amgen Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-01-31_to_2022-01-31">Thousand Oaks</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-01-31_to_2022-01-31">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-01-31_to_2022-01-31">91320-1799</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-01-31_to_2022-01-31">(805)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-01-31_to_2022-01-31">447-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-01-31_to_2022-01-31">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-01-31_to_2022-01-31">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-01-31_to_2022-01-31">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-01-31_to_2022-01-31">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-01-31_to_2022-01-31_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-01-31_to_2022-01-31_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">AMGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-01-31_to_2022-01-31_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2022-01-31_to_2022-01-31_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">2.000% Senior Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-01-31_to_2022-01-31_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">AMGN26</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-01-31_to_2022-01-31_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-01-31_to_2022-01-31">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M]USQ+#T<EEG>Q>%A!^SG<;T^4S]<KXZ,EFV XI[]'[*IUBF0U0'6R-8"EEV
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M .?7$FIRW+%??HH/=\-_ %!+ P04    " "Q@S]4GZ ;\+$"  #B#   #0
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M/[&\UDX:?^:+X3]>?P%02P$"% ,4    " "Q@S]4!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( +&#
M/U0VN$Y:[0   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( +&#/U297)PC$ 8  )PG   3              "
M <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ L8,_5.15-T.C
M!   Q!,  !@              ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( +&#/U2?H!OPL0(  .(,   -              "
M >4,  !X;"]S='EL97,N>&UL4$L! A0#%     @ L8,_5)>*NQS     $P(
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9>&UL4$L%!@     )  D /@(  $44      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>118</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d275986d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d275986d8k.htm">d275986d8k.htm</File>
    <File>amgn-20220131.xsd</File>
    <File>amgn-20220131_def.xml</File>
    <File>amgn-20220131_lab.xml</File>
    <File>amgn-20220131_pre.xml</File>
    <File>d275986dex101.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d275986d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "amgn-20220131_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d275986d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amgn-20220131_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amgn-20220131_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "amgn-20220131.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 118,
   "memberCustom": 1,
   "memberStandard": 1,
   "nsprefix": "amgn",
   "nsuri": "http://www.amgen.com/20220131",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d275986d8k.htm",
      "contextRef": "duration_2022-01-31_to_2022-01-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d275986d8k.htm",
      "contextRef": "duration_2022-01-31_to_2022-01-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "amgn_A2.00SeniorNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A 2.00 Senior Notes Due 2026 [Member]",
        "terseLabel": "A 2.00 Senior Notes Due 2026 [Member]"
       }
      }
     },
     "localname": "A2.00SeniorNotesDue2026Member",
     "nsuri": "http://www.amgen.com/20220131",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_DocumentAndEntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationLineItems",
     "nsuri": "http://www.amgen.com/20220131",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_DocumentAndEntityInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationTable",
     "nsuri": "http://www.amgen.com/20220131",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com//20220131/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-22-023401-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-023401-xbrl.zip
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M %&,%711*P@#$XA:W5:[VSE%_6MT:5$8&I$$UC/Y?"G(=*;0C]%/R"9=<,:
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MS\(NDRHA[;%B1S+Z%9=\N,<:]%X ARR-.$>3;G)<DN$F,L%.#<U(9&HNP!,
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MAIJ[V#!$N8*Z0OH>> /L^7G]3F\F!-]8H)]J*![.\+$&+T&9]HRI]EB5B2O
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MI=/4>^0C"YBD/L$;HQ7S;9["E2P"G9R;#\V)L4[*YH]?ZC^->?;_4$L#!!0
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MIG[@.9R]:1P?'1XT?GOSQF+7PV8&?6 <8[7U] "2=5<KN%;![1D+Q%0$B%:
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MA.<6R!Z55&N5@-.B 2_%Q+&!;IO3*7<"8-[(\QQ:/I"BQ=X'W+.!JPL-<-8
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MCER1N*5V7P:T@*?:&0Q90@O*%4!5HM)#7C,+GP#?7!K%EO5P"<P3=I#905(
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M&%L;=3+93ZX:H6Y2U<J*YEC[8)]$CBMU_0CVH"N?X<62I1BUL$F;,%W?8_3
M?(BH+&OJT<C&_HGB<1Q,[&%@,V UKP2DEJ WT@@5U'V^6GEX-ZU]>6'*TQJ)
M/ )) $N:B55:!G1<)O5$H1*D /4)[*!N!+(3Y-(]DC1V;>L1UEFF#IP_9O\)
M:=TYV"=):+<7F)<9,D/0%(&PK.E)+=??I-;87S=4'F0;**V/1/S215<K#=D
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M#@PF R1P*\Z;_&1,7?+KPR>7)_UAT&Y?PI060A,/AB#*AM=G'Q&.E\T1Z $
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M!;Z\&%UV3_\?4$L! A0#%     @ L8,_5);V\,P,!   2!   !$
M     ( !     &%M9VXM,C R,C Q,S$N>'-D4$L! A0#%     @ L8,_5(\9
M.\;(!0  %S0  !4              ( !.P0  &%M9VXM,C R,C Q,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( +&#/U0OML=]S <  !-6   5              "
M 38*  !A;6=N+3(P,C(P,3,Q7VQA8BYX;6Q02P$"% ,4    " "Q@S]4DR2F
M88(%  ":-P  %0              @ $U$@  86UG;BTR,#(R,#$S,5]P<F4N
M>&UL4$L! A0#%     @ L8,_5#99B-H4$@  M78   X              ( !
MZA<  &0R-S4Y.#9D.&LN:'1M4$L! A0#%     @ L8,_5"[D.;KT)P  L_4
M !$              ( !*BH  &0R-S4Y.#9D97@Q,#$N:'1M4$L%!@     &
-  8 @P$  $U2      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
